Here is a Group of articles from the WSJ that are accessible on GLP-1’s as the ultimate anti-aging drug. Ozempic just approved for kidney disease, heart disease as well as diabetes regardless of weight loss. Cancer and many more to come. Many articles on GLP-1’s including one’s in the trial pipeline. I get WSJ electronic subscription for 50 cents week. This link is a gift for all. If you sign up for free WSJ Newsletter in the article you will have access to all the other articles listed. WSJ and NY Times are some of few newspapers left that have the money to research articles of interest.
5 Likes
Derek Thompson hosted an interview with Eli Lilly’s (which didn’t make Ozempic, but other GLP-1 and GIP agonists) CEO David Ricks for his Plain English podcast:
They discuss the effect of these compounds on a whole host of conditions. e.g.
-
“We have a study where we watch people on Tirzepatide for three years and they had 92% less diabetes at the end of the study.”
-
How they drop hsCRP 50% to 70%.
-
" I mean, it was the most effective osteoarthritis knee pain drug I think ever studied."
-
“Psoriasis a skin inflammation disease. psoriatic arthritis, a version of that that appears in your joints.
Here again, the drug Zepound boosted that performance by 50% almost as good as adding an entirely new drug class um to that category.” -
Possible reduction in cancer rates – maybe due to the weight loss, maybe due to anti-inflammatory effects.
-
It appears to reduce compulsive gambling and shopping; and they’re doing prospective studies to show that it reduces (excessive) alcohol use and helps with reducing smoking.
-
They’re testing the effect on Alzheimer’s, and are currently into the 5th year of the test.
All of that and more from one class of drugs!
2 Likes